DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,298 filers reported holding DANAHER CORPORATION in Q4 2018. The put-call ratio across all filers is 1.15 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $4,428,591 | +0.1% | 17,725 | 0.0% | 1.80% | +3.4% |
Q1 2024 | $4,426,287 | +27.8% | 17,725 | +18.4% | 1.74% | +16.6% |
Q4 2023 | $3,464,317 | +27.2% | 14,975 | +36.4% | 1.49% | +181.5% |
Q3 2023 | $2,722,898 | +3.4% | 10,975 | 0.0% | 0.53% | +20.7% |
Q2 2023 | $2,634,000 | -10.1% | 10,975 | -5.6% | 0.44% | -22.0% |
Q1 2023 | $2,929,965 | -5.0% | 11,625 | 0.0% | 0.56% | -5.7% |
Q4 2022 | $3,085,508 | +38.5% | 11,625 | +34.8% | 0.60% | +36.0% |
Q3 2022 | $2,228,000 | +1.9% | 8,625 | 0.0% | 0.44% | -0.5% |
Q2 2022 | $2,187,000 | -50.5% | 8,625 | -42.8% | 0.44% | -43.8% |
Q1 2022 | $4,422,000 | -19.9% | 15,075 | -10.1% | 0.78% | -5.5% |
Q4 2021 | $5,519,000 | +8.1% | 16,775 | 0.0% | 0.83% | +95.5% |
Q3 2021 | $5,107,000 | +13.4% | 16,775 | 0.0% | 0.42% | +16.8% |
Q2 2021 | $4,502,000 | +19.2% | 16,775 | 0.0% | 0.36% | +27.3% |
Q1 2021 | $3,776,000 | +126.7% | 16,775 | +123.7% | 0.29% | +144.4% |
Q4 2020 | $1,666,000 | +3.2% | 7,500 | 0.0% | 0.12% | -15.8% |
Q3 2020 | $1,615,000 | +318.4% | 7,500 | +110.9% | 0.14% | +239.0% |
Q3 2018 | $386,000 | – | 3,556 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ace Management Global Ltd. | 168,488 | $42,096,727 | 12.36% |
Zeno Equity Partners LLP | 182,612 | $45,660,122 | 12.15% |
Defender Capital, LLC. | 135,187 | $33,776,567 | 11.54% |
Bancreek Capital Management, LP | 56,267 | $14,058,310 | 10.98% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 214,830 | $53,664,407 | 9.84% |
CADEN CAPITAL PARTNERS, LP | 104,501 | $26,109,575 | 9.44% |
Dorsey Asset Management | 306,420 | $76,559,037 | 9.12% |
Consulta Ltd | 500,000 | $124,925,000 | 8.51% |
BOONE CAPITAL MANAGEMENT LLC | 106,360 | $26,574,046 | 6.93% |
Manchester Global Management (UK) Ltd | 150,688 | $37,649,397 | 6.62% |